Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis
Article excerpt
Calytrix Bio's potentially best-in-class preclinical program is a novel biparatopic antibody designed to deliver pan-mutant calreticulin activity Acquisition broadens Lilly's presence in the myeloproliferative neoplasm field and builds on Lilly's established capabilities in blood cancers WELLESLEY, Mass., Nov. 16, 2026 /PRNewswire/ -- Calytrix Bio, Inc. ("Calytrix"), a company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Eli Lilly and Company ("Lilly") to acquire Calytrix. Calytrix's lead asset is an investigational biparatopic antibody for mutant calreticulin (mCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). It is designed to deliver disease-modifying pan-mutant activity, with a safety and convenience profile that supports early intervention and long-term treatment. Current drug therapies for ET and MF primarily manage symptoms and complications, creating an opportunity for precision therapies that target the disease driver mutations. Mutant CALR provides a tumor-specific cell-surface target with the potential to deplete the disease-driving mutant clone while sparing normal tissues and preserving healthy hematopoiesis. "Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad...
Keep reading with a free account
The rest of this article, and every signal for Eli Lilly, is in your free account.
Extracted from this sentence
Under the terms of the agreement, Lilly will acquire Calytrix, and Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.
